ASCO2023
The trial compared ciltacabtagene autoleucel with standard of care in patients with MM who were refractory to lenalidomide.
The researchers used a 3+3 study design to determine the maximum tolerated dose of CC-486 plus venetoclax.
SAR’579 targets CD123 and co-engages NKp46 and CD16a on natural killer cells.
Advertisement
Dr. Nabhan, who hosts The HemOnc Pulse, discusses the podcast and what he hopes listeners gain from it at ASCO 2023.
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Dr. Nabhan also speaks about his next book, which is expected to be released in fall 2024.
Advertisement
The retrospective review was conducted by abstracting data from the medical charts of patients with Burkitt lymphoma.
Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive ATL who were not candidates for allogeneic HSCT.
Less than half of patients had “clinically significant” CMV reactivation that required antiviral therapy.
With four years of follow-up data, the best complete response rate was 58%.
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
The study included patients who underwent an evaluation for allogeneic HSCT at a large academic medical center.
The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks.
Jennifer Woyach, MD and colleagues presented the study's results during the 2023 ASCO Annual Meeting.
Most patients (82%) had a low transfusion burden at baseline.
Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting.
A subset of TP53-mutated myeloid neoplasms, such as MDS, are preceded by TP53-mutated CCUS.
Nearly one-third (29%) of patients were upstaged from their IPSS-R score by the IPSS-M.
Dr. Garcia-Manero presented information about a phase Ib study of IRAK1/4 inhibition at the 2023 ASCO Annual Meeting.
Pola-R-CHP and R-CHOP “demonstrated similar safety profiles” in older adults with previously untreated DLBCL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.